CHEK2 Gene Variant Possibly Linked to Risk of Developing Clear Cell Kidney Cancer
Is Monosomy of Chromosome 9 Linked to Adverse Outcomes in Renal Cell Carcinoma?
RTK Inhibitor Plus Immunotherapy in Advanced Kidney Cancer
FDA Accepts Biologics License Application for Proposed Biosimilar To Bevacizumab
Combined Presence of Kidney Cancer and Myeloma: Two Clinical Cases
Metastatic Abscesses During Pazopanib Treatment: An Underdescribed Risk?
Perioperative Change in Renal Function: Prognostic Indicator in Renal Cell Carcinoma?
HIF-2α Protein and Progression of Clear Cell Kidney Cancer
Active Surveillance Safe for Small Renal Tumors
PD-1 Inhibitor Disappoints in mRCC With Untreated Brain Metastases
NCCN Guidelines® Insights – Kidney Cancer, Version 2.2020
NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
Memorial Sloan Kettering Cancer Center
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Yale Cancer Center / Smilow Cancer Hospital
Lenvatinib Plus Everolimus (Renal Cell Carcinoma)
Cabozantinib (Renal Cell Carcinoma)
Nivolumab + Ipilimumab (Renal Cell Carcinoma)
Cancer.gov: What You Need To Know About Kidney Cancer
ASCO: COVID-19 Medical Resources
NCCN Guidelines for Patients®
NCCN Guidelines for Patients Kidney Cancer—Quick Guide